Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-04
1995-11-21
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31505
Patent
active
054687527
ABSTRACT:
Treatment of conditions of abnormally increased intraocular pressure, particularly those caused by glaucoma, by administration of a phosphonylmethoxypropyl cytosine compound, preferably (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine [HPMPC], is disclosed. The cytosine compounds may be present preferably as a free drug or alternatively encapsulated into liposomes or other :long acting drug delivery systems, Administration of the compound may be by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, or by topical drops, in an inert carrier. The degree of reduction in pressure is dosage-dependent, and significant reduction in pressure is obtained. A single injection is expected to be sufficient to produced prolonged, and perhaps permanent, lowering of the intraocular pressure, although in some cases additional injections may be required at infrequent intervals. The amount of the compound administered may be varied by the physician to obtain the desired degree of pressure decrease. Also disclosed are the compositions used in the method.
REFERENCES:
patent: 4230708 (1980-10-01), De Clercq et al.
patent: 4605658 (1986-08-01), Holy et al.
patent: 4724233 (1988-02-01), De Clercq et al.
patent: 5142051 (1992-08-01), Holy et al.
Chemical Abstract 119: 151515 (1993). Clercq.
Andrei, et al., "Comparative Activity of Selected Antiviral Compounds against Clinical Isolates of Human Cytomagalovirus," Eur. J. Clin. Microbiol. Infect. Dis. 10(12):1026-1033 (1991).
Cantrill, et al., "Treatment of Cytomegalovirus Retinitis with Intravitreal Ganciclovir," Ophthalmology 96(3):367-374 (1989).
Erik De Clercq, "Broad-Spectrum Anti-DNA Virus and Anti-Retrovirus Activity of Phosphonylmethoxyalkylpurines and --Pyrimidines," Biochem. Pharm. 42(5):963-972 (1991).
William R. Freeman, "Intraocular Antiviral Therapy," Arch. Ophthalmol. 107:1737-1739 (1989).
Friberg and Paul, "CMV Retinitis and Immunosuppression with FK506," Retina/Anatomy & Pathology/Clinical Res./Immunology & Microbiology Paper Presentation 291:11:15 (Abstract), Investigative Ophthalmology & Visual Science, Annual Meeting Abstract Issue, May 3-8, 1992, Sarasota, Fla.
Freeman, et al., "HPMPC for the Long Acting Treatment of Experimental Herpes Simplex Retinitis in Rabbits," 292:11:30 (Abstract), Investigative Ophthalmology & Visual Science, Annual Meeting Abstract Issue, May 3-8, 1992, Sarasota, Fla.
Gross, et al., "Longitudinal Study of Cytomegalovirus Retinitis in Acquired Immune Deficiency Syndrome," Ophthalmology 97:681-686 (1990).
Henderly, et al., "Cytomegalovirus Retinitis and Response to Therapy With Ganciclovir," Ophthalmology 94(4):425-434 (1987).
Henry, et al., "Use of Intravitreal Ganciclovir (Dihydroxy Propoxymethyl Guanine) for Cytomegalovirus Retinitis in a Patient With AIDS," Am. J. Ophthal. 103(1):17-23 (1987).
Douglas A. Jabs, "Treatment of Cytomegalovirus Retinitis-1992," Arch. Ophthalmol. 110:185-187 (1992).
Maudgal and De Clercq, "(S)-1-(3-Hydroxy-2-Phosphonyl-Methoxypropyl)Cytosine in the Therapy of Thymidine Kinase-Positive and -Deficient Herpes Simplex Virus Experimental Keratitis," Investigative Ophthalmol. & Visual Sci. 32(6):1816-1820 (1991).
Neyts, et al., "Selective Inhibition of Human Cytomegalovirus DNA Synthesis by (S)--1--(3--Hydroxy--2--phosphonylmethoxypropyl)cytosine [(S)--HPMPC] and 9--(1,3--Dihydroxy--2--propoxymethyl)guanine (DHPG)," Virology 179:41-50 (1990).
Neyts, et al., "Efficacy of (S)--1--(3--Hydroxy--2--Phosphonylmethoxypropyl)Cytosine and 9--(1,3--Dihydroxy--2--Propoxymethyl)Guanine for the Treatment of Murine Cytomegalovirus Infection in Severe Combined Immunodeficiency Mice," J. Med. Virol. 37:67-71 (1992).
Sanborn, et al., "Substained-Release Ganciclovir Therapy for Treatment of Cytomegalovirus Retinitis," Arch. Ophthalmol. 110:118-195 (1992).
Smith, et al., "Intravitreal Sustained-Release Ganciclovir," Arch. Opthalmol. 110:225-258 (1992).
Ussery, et al., "Intravitreal Ganciclovir in the Treatment of AIDS-associated Cytomegalovirus Retinitis," Ophthalmology 95(5):640-648 (1988).
Andreoli, et al., editors, Cecil Essentials of Medicine W.B. Saunders Company, publishers, pp. 690-691 (1986).
Leibrandt, editor, Professional Guide to Disease, pp. 1203-1206 (1982).
Berthe, et al., "Toxicologic and Pharmacokinetic Analysis of Intravitreal Injections of Foscarnet, Either Alone or in Combination With Ganciclovir," Invest. Ophthal. & Visual Sci. 35(3):1038-1045 (1994).
De Clercq, Erik, "Antivirals for the treatment of herpesvirus Infections," J. Antimicrobial Chemotherapy 32(A):121-132 (1993).
Diaz-Llopis, et al., "Intravitreal Foscarnet for Cytomegalovirus Retinitis in a Patient With Acquired Immunodeficiency Syndrome," American J. of Ophthalmology 115(5):686-688 (1993).
Li, et al., "Activity of (S)--1--(3--hydroxy--2--phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs," Antiviral Research 13:237-252 (1990).
Saffar, et al., "Transscleral Iontophoresis of Foscarnet," American J. of Ophthalmology 115:748-754 (1993).
Neyts, et al., "Efficacy of (S)--1--(3--Hydroxy--2--Phosphonylmethoxypropyl)Cytosine and 9--(1,3--Dihydroxy--2--Propoxymethyl)Guanine for the Treatment of Murine Cytomegalovirus Infection in Severe Combined Immunodeficiency Mice," J. of Medical Virology 37:67-71 (1992).
Shigeta, et al., "Comparative Inhibitory Effects of Nucleoside Analogues on Different Clinical Isolates of Human Cytomegalovirus in Vitro," J. of Infectious Diseases 163:270-275 (1991).
Fay Zohreh
Seidman Stephanie L.
LandOfFree
Treatment of conditions of abnormally increased intraocular pres does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of conditions of abnormally increased intraocular pres, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of conditions of abnormally increased intraocular pres will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1137347